...
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs.
【24h】

Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs.

机译:微量白蛋白尿在原发性高血压中。通过不同的降压药减少。

获取原文

摘要

The effects of four different antihypertensive drugs (the Ca(2+)-channel blocker felodipine, the beta-blocker metoprolol, the angiotensin converting enzyme inhibitor ramipril, and the alpha-blocking agent doxazosin) on microalbuminuria and renal hemodynamics were evaluated in a double-blind, crossover study in 17 patients (10 women, seven men, aged 39 +/- 14 years) with mild-to-moderate essential arterial hypertension and microalbuminuria. Patients were studied after a 2-week placebo phase preceded by 2 weeks off all medication and after 12 weeks of treatment with each drug. Between each drug treatment, there was another 14-day placebo washout period. At the end of the study, we performed two additional 2-week placebo periods. After each placebo and treatment period, we measured albumin excretion during a 3-day collecting period. Renal hemodynamics were assessed by clearance techniques (inulin and p-aminohippurate clearance) at the end of the first and last placebo periods and after each treatment period. All drugs reduced mean arterial pressure and microalbuminuria to a similar and statistically significant (p < 0.05) extent (mean arterial pressure: placebo phase, 116 +/- 5 mm Hg; felodipine, 101 +/- 4 mm Hg; metoprolol, 101 +/- 5 mm Hg; ramipril, 101 +/- 4 mm Hg; doxazosin, 102 +/- 5 mm Hg; urinary albumin excretion: placebo phase, 46 +/- 50 mg/day; felodipine, 18 +/- 23 mg/day; metoprolol, 14 +/- 12 mg/day; ramipril, 16 +/- 16 mg/day; doxazosin, 14 +/- 14 mg/day). Mean arterial pressure levels and urinary albumin excretion returned to baseline after the last placebo period (110 +/- 6 mm Hg and 40 +/- 46 mg/day, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
机译:双重评估了四种不同的降压药(Ca(2+)通道阻滞剂非洛地平,β阻滞剂美托洛尔,血管紧张素转化酶抑制剂雷米普利和α阻滞剂多沙唑嗪)对微量白蛋白尿和肾脏血液动力学的影响。对17例轻度至中度原发性高血压和微量白蛋白尿患者(10名女性,7名男性,年龄在39 +/- 14岁)进行盲,交叉研究。在2周的安慰剂阶段后,对所有药物停药2周以及每种药物治疗12周后,对患者进行了研究。在每次药物治疗之间,还有另一个14天的安慰剂清除期。在研究结束时,我们进行了另外两个为期2周的安慰剂治疗。在每个安慰剂和治疗期后,我们在3天的收集期内测量了白蛋白排泄。在第一个和最后一个安慰剂阶段结束时以及每个治疗阶段之后,通过清除技术(菊粉和对氨基马尿酸盐清除)评估肾脏血液动力学。所有药物均将平均动脉压和微白蛋白尿降低至相似且具有统计学意义(p <0.05)的程度(平均动脉压:安慰剂相116 +/- 5 mm Hg;非洛地平101 +/- 4 mm Hg;美托洛尔101 + -/-5毫米汞柱;雷米普利,101 +/- 4毫米汞柱;多沙唑嗪,102 +/- 5毫米汞柱;尿白蛋白排泄:安慰剂相,46 +/- 50毫克/天;非洛地平,18 +/- 23毫克/天;美托洛尔,14 +/- 12毫克/天;雷米普利,16 +/- 16毫克/天;多沙唑嗪,14 +/- 14毫克/天。在最后一次安慰剂治疗后(分别为110 +/- 6 mm Hg和40 +/- 46 mg / day),平均动脉压水平和尿白蛋白排泄恢复到基线。(摘要截断为250字)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号